Genmab — Juni 2020
-
Genmabs poster discussions on epcoritamab (DuoBody
-CD3xCD20), HexaBody-CD38, and DuoHexaBody-CD37 are now
available to view on demand. https://ehaweb.org/congress/eha25/virtual/ -
Gode data fra vores venner Abbvie i psoriasis https://finance.yahoo.com/news/abbvie-presents-breaking-data-showing-190200489.html
-
Dr Hari on the role of MRD in MM. https://www.onclive.com/view/dr-hari-on-the-role-of-mrd-in-multiple-myeloma?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==
-
Adding Daratumumab to CyBorD Improves Outcomes for AL Amyloidosis https://www.onclive.com/view/adding-daratumumab-to-cybord-improves-outcomes-for-al-amyloidosis
-
HexaBody
Technology Platform https://www.youtube.com/watch?v=33LiakTF9cs -
this is the small biotech fund investment
i referred to a few days ago https://twitter.com/Genmab/status/1271505500165885952 -
EHA: Johnson & Johnson's Darzalex branches out beyond myeloma with AL amyloidosis win https://www.fiercepharma.com/pharma/eha-johnson-johnson-s-darzalex-branches-out-beyond-myeloma-al-amyloidosis-win?utm_source=dlvr.it&utm_medium=twitter
-
Interessant kommentar fra Martin Hutchings „CR is almost surely underestimated, particularly in FL“ https://twitter.com/dochutchings/status/1271521705400377346?s=21
-
Showing examples of Genmab's bispecific antibody technology by Janssen https://twitter.com/raintank2010/status/1271708344965754881?s=21
-
poster on DuoHexaBody
-CD37 https://twitter.com/genmab/status/1271765526268776449?s=21 -
jeg kunne heller ikke komme igennem uden kode
-
daratumumab reduces risk of progression or death by 33% in patients with NDMM and high cytogenetic risk https://twitter.com/end_myeloma/status/1271800157017866240?s=21
-
Investigator-assessed betyder at det er lægen i stedet for "metoden" der bestemmer at patienten er i CR. Nogen gange er det måske helt fair da metoden eller definitionerne kan være komplicerede og med de komplicerede stoffer der gives i dag kan det være noget af en gråzone set ud fra et lægefagligt og patientmæssigt aspekt. Men det kan jo altid diskuteres hvor grænserne går, jeg blander mig ikke i den diskussion.
-
En glad redaktør i hovedkvarteret lige nu. Har sent i går aftes overtaget Facebookgruppen "Genmab shareholders/aktionærer". En stor tak til stifterne Marcus Siefert og Joachim Vinter som har. De har gjort et solidt stykke arbejde. Gruppen bliver nu en del af mit og Proinvestors sociale medieunivers inden for aktier og investering.
Blev medlem her: https://www.facebook.com/groups/1814736572095032
-
Tanken er at gruppen skal fungere som supplement og trafikkanal til vores chat her på PI. Det er nu engang her fingeren for alvor er på Genmabs puls.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind